Anti-erythropoietin antibody–mediated pure red cell aplasia in a living donor liver transplant recipient treated for hepatitis C virus
✍ Scribed by Jordan M. Schecter; J. Gregory Mears; Bachir Alobeid; Paul J. Gaglio
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 91 KB
- Volume
- 13
- Category
- Article
- ISSN
- 1527-6465
- DOI
- 10.1002/lt.21332
No coin nor oath required. For personal study only.
✦ Synopsis
After liver transplantation, reinfection of the newly engrafted liver with hepatitis C virus is essentially universal in patients who are viremic at the time of transplantation. Treatment with interferon preparations with or without ribavirin is recommended in patients with marked histologic injury; however, hematologic toxicity associated with therapy has been reported, which is usually treated with growth factor support, including erythropoietin analogues. We present the first reported case of antierythropoietin antibody-mediated pure red cell aplasia arising in the setting of hepatitis C virus therapy in a patient who underwent living donor liver transplantation.